The role of aging for α-synuclein oligomer accumulation in a mouse model for parkinson’s disease

Read full text Summarise with VIRAT
Authors: Verena Bopp
Cited by: 0
References: 307

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aging is a key risk factor for Parkinson’s disease (PD), with its symptoms progressively worsening over time. A central feature of PD is the accumulation of misfolded α-synuclein (α-syn). This study investigated whether advanced age or prolonged exposure to α-syn oligomers is the primary contributor to motor dysfunctions in PD, employing a mouse model of α-syn oligomerization and advanced tools like single-nucleus RNA sequencing (snRNA-seq) and mass spectrometry (MassSpec). Motor deficits observed in the PD mouse model (S1/S2) were found to be predominantly age-dependent. Lifelong expression of S1/S2 oligomers in 16 and 24 M old mice resulted in severe motor impairments. Even brief oligomer exposure in older animals was sufficient to induce deficits, emphasizing the significant influence of aging. Interestingly, endogenous α-syn levels showed compensatory decreases with age and S1/S2 expression, but no direct correlation was observed between α-syn oligomer levels and motor symptoms. Oligomer formation, detected across all ages, appeared to precede motor dysfunction without a direct relationship to symptom severity. These findings indicate that aging, coupled with a baseline level of oligomerization, plays a decisive role in symptom onset and severity. SnRNA-seq identified GABAergic Rgs9 neurons as critical to PD pathology, showing the highest expression of the S1/S2 transgene. Differential gene expression (DGE) analysis of Rgs9 neurons revealed upstream pathway disruptions associated with S1/S2 expression, such as altered cAMP and calcium signaling. These disturbances likely cascade into proteasomal dysfunction and axonal transport impairments, driving motor deficits. Notably, genes linked to cAMP signaling were altered before symptom onset, suggesting their role in PD initiation. Proteostasis disruption, marked by reduced proteasomal activity, was confirmed through biochemical analysis. To distinguish aging-specific effects, an Aging Signature was derived from non-expressing controls, revealing oxidative damage as an upstream factor affecting ribosomal and proteasomal genes. The interplay between PD and aging showed overlapping disruptions in pathways such as calcium signaling, proteasome function and oxidative stress. Six key regulators, identified as Pathological Aging genes, were implicated in both aging and PD. Their expression patterns, downregulated with aging but upregulated in PD, suggest compensatory mechanisms during disease progression. Given the overlap between aging-related disruptions and PD pathology, the study explored the inhibition of the age-associated protein Cdc42 using Cdc42 activity-specific inhibitor (CASIN). Cdc42 is a Rho GTPase involved in actin dynamics, cell polarity and reactive oxygen species (ROS) regulation. CASIN treatment yielded significant motor improvements in older S1/S2 mice (16 and 24 M), while having minimal impact on young mice or α-syn oligomer levels. This suggests that Cdc42 inhibition exerts its therapeutic effects through age-modulating mechanisms rather than directly affecting α-syn oligomerization. The study also investigated immune alterations with age and CASIN’s potential to reverse these changes. Age-related declines in naïve T-cell populations, increases in memory T-cells and age-associated B-cells (ABCs) and shifts in regulatory T-cells (Tregs) were observed. CASIN selectively rejuvenated immune populations, restoring youthful levels of naïve T-cells and suppressing ABC accumulation. However, the effects were more pronounced in non-expressing controls than in S1/S2-expressing animals, indicating potential interactions between α-syn oligomers and immune pathways. The findings underscore the complexity of aging and PD, highlighting age as a pivotal factor in disease severity. Future work should focus on elucidating the precise molecular pathways linking aging, α-syn oligomerization and motor deficits. Single-cell analysis of identified pathological genes may uncover new targets for intervention. While CASIN’s therapeutic effects are promising, further studies are needed to refine its application and understand its mechanism. By bridging aging and PD through shared molecular mechanisms, this research lays the groundwork for developing interventions that address both conditions, ultimately improving outcomes for aging populations at risk of neurodegenerative diseases.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Nuclear Receptors and Signaling Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Publication date
27 March 2026
Language
EN
Document type
Thesis